about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Chi­nese vac­cine de­vel­op­ers have be­gun to shed some se­cre­cy around Covid-19 can­di­dates. What do we know?

5 years ago
China
Coronavirus

Avid­i­ty tops up IPO at $298M; Bris­tol My­ers keeps a Cel­gene dis­cov­ery pact alive

5 years ago
News Briefing

Mer­ck eats the lunch Bris­tol My­ers nev­er served, win­ning TMB-based OK for Keytru­da

5 years ago
Pharma

All in on IL-11, Fra­zier un­veils lat­est start­up with dual fo­cus on fi­bro­sis and can­cer

5 years ago
Financing
Startups

Pablo cap­i­tal­ized: Roy­al­ty Phar­ma scores $2.2B IPO — the biggest of the year

5 years ago
Financing

Covid-19 roundup: An old, cheap steroid proves to be a ma­jor boon to coro­n­avirus pa­tients; BAR­DA puts $85M be­hind ...

5 years ago
Coronavirus

It's not just Charles Lieber: NI­H's on­go­ing in­ves­ti­ga­tion has swept up 54 sci­en­tists who vi­o­lat­ed rules about for­eign ...

5 years ago
China

SK Bio­phar­ma­ceu­ti­cals emerges from pan­dem­ic with pitch for $822M IPO

5 years ago
Financing

On a hir­ing spree, Mod­er­na re­cruits an­oth­er Am­gen vet for the ex­ec­u­tive com­mit­tee; Re­pare, For­ma set terms for IPO

5 years ago
News Briefing

Covid-19 roundup: Catal­ent lends vac­cine pro­duc­tion ca­pac­i­ty to As­traZeneca/Ox­ford for hun­dreds of mil­lions dos­es

5 years ago
Financing
Coronavirus

'Ris­ing star' CEO re­counts path from pre-med to break­through meds; Den­dreon taps Big Phar­ma vet Ja­son O'Neill as CEO

5 years ago
Peer Review

Mod­er­na bur­nish­es its PhI­II-ready Covid-19 vac­cine with promis­ing mouse da­ta — which sug­gest one dose might be ...

5 years ago
R&D
Coronavirus

Covid-19 roundup: Chi­na's Sino­vac goes to Brazil for PhI­II; As­traZeneca signs Emer­gent on for $87M man­u­fac­tur­ing deal

5 years ago
Coronavirus

Lenti­Glo­bin con­tin­ues to de­liv­er in lat­est sick­le cell up­date as blue­bird out­lines path to ac­cel­er­at­ed ap­proval, ...

5 years ago
R&D
Cell/Gene Tx

Covid-19 roundup: Re­gen­eron puts its an­ti­bod­ies in­to the clin­ic, rac­ing with Eli Lil­ly for fall au­tho­riza­tion

5 years ago
Coronavirus

A sto­ried Chi­nese phar­ma part­ner of Bris­tol My­ers, Am­gen — and avid biotech sup­port­er — plots HK IPO

5 years ago
Financing
China

'Tremen­dous' an­i­mal da­ta in­spire GV, ARCH's $63M boost­er for Sekar Kathire­san's dri­ve to rel­e­gate coro­nary heart ...

5 years ago
Financing

Fu­ji­film dou­bles down on ex-Bio­gen fa­cil­i­ty with $928M in­fu­sion as biotech boom fu­els CD­MO growth

5 years ago
Outsourcing

Har­vard's Charles Lieber in­dict­ed for ly­ing to the feds, bring­ing US re­searcher­s' Chi­na ties back to the spot­light

5 years ago
People
China

Go­ing where PRO­TACs can't, Ver­sant un­veils $50M bet on Car­olyn Bertozzi's LY­TAC tech — with a ris­ing star at the ...

5 years ago
Financing
Startups

Lean­ing on BD to re­vive weak pipeline, Lund­beck plans to cut up to 160 jobs in R&D re­struc­tur­ing

5 years ago
People
R&D

CSL Behring snaps up a close­ly-held biotech part­ner and its IL-6 drug — for trans­plant re­jec­tion

5 years ago
Deals

Nim­bus picks 4 pre­clin­i­cal tar­gets for the next chap­ter of its pi­o­neer­ing com­pu­ta­tion­al drug dis­cov­ery work

5 years ago
Discovery

Months af­ter steer­ing a seizure res­cue ther­a­py to mar­ket, UCB bags an­oth­er promis­ing late-stage as­set for $125M ...

5 years ago
Deals
First page Previous page 73747576777879 Next page Last page
A service from the Financial Times